Abstract:Objective: To investigate the significance of the maximum standardized uptake value (SUVmax) of single photon emission computed tomography(SPECT)/computed tomography(CT), serum alkaline phosphatase (ALP), N-terminal intermediate molecular fragment of osteocalcin (N-MID), and total type I procollagen N-terminal prepreptide (TPINP) in patients with bone metastasis from lung cancer. Methods: A total of 107 lung cancer patients treated in our hospital from January 2021 to June 2022 were selected, including 37 patients with bone metastasis and 70 patients without bone metastasis, the differences of SUVmax, ALP, N-MID and TPINP between patients with bone metastasis and patients without bone metastasis were compared, and the relationship between SUVmax, ALP, N-MID and TPINP and clinicopathological characteristics was analyzed, as well as the value of ALP, N-MID and TPINP in diagnosing bone metastasis. Results: The ALP, N-MID and TPINP of patients with bone metastasis were (120.30 ± 33.32) U/L, (19.03 ± 3.54) μg/L and (82.21 ± 26.65) μg/L, respectively, which were significantly higher than those of patients without bone metastasis (P<0.05), while the lumbar bone mineral density (BMD) was (0.82 ± 0.12), (0.74 ± 0.11) and (0.66 ± 0.14), respectively, which was significantly lower than that of patients without bone metastasis (P<0.05). SUVmax in patients with adenocarcinoma was (11.45 ± 1.98), which was significantly lower than that in patients with squamous cell carcinoma and other types (P<0.05). The SUVmax of tumor diameter>5cm and TNM stage Ⅲ~Ⅳ were (13.38 ± 1.95) and (12.99 ± 2.00) respectively, which were significantly higher than those of patients with treatment diameter ≤ 5cm and TNM stage Ⅰ~Ⅱ (P<0.05). ALP, N-MID and TPINP in TNM stage Ⅲ~Ⅳ were (110.39 ± 21.12) U/L, (18.62 ± 2.22) μg/L and (70.31 ± 17.02) μg/L respectively, which were significantly higher than those in TNM stage Ⅰ~Ⅱ patients (P<0.05). The area under ROC curve of ALP, N-MID and TPINP in diagnosing bone metastasis was 0.695, 0.734 and 0.837 respectively (P<0.05). Conclusion: Compared with lung cancer patients with without bone metastasis, the levels of ALP, N-MID and TPINP in lung cancer patients with bone metastasis are significantly higher, while SUVmax has no significant difference; SUVmax, ALP, N-MID and TPINP have a certain relationship with the clinicopathological characteristics of lung cancer patients. Among them, ALP, N-MID and TPINP have a certain application value in the diagnosis of bone metastasis of lung cancer.
谭国威, 于青禾, 顾虹. 肺癌骨转移患者SPECT/CT最大标准化摄取值及血清ALP N-MID TPINP水平及意义分析[J]. 河北医学, 2023, 29(5): 808-814.
TAN Guowei, et al. Maximum Standardized Uptake Value of SPECT/CT and Serum ALP N-MID TPINP Levels in Patients with Lung Cancer Bone Metastasis and Their Significance. HeBei Med, 2023, 29(5): 808-814.
[1] Siegel RL,Miller KD,Fuchs HE,et al.Cancer statistics,2022[J].CA Cancer Clin,2022,72(1):7-33. [2] 唐敏,杨银静,李桂香.肺癌骨转移预测指标及预测模型研究进展[J].中国现代医药杂志,2021,23(11):105-108. [3] Ettinger DS,Wood DE,Aisner DL,et al.Non-small cell lung cancer,version 3.2022,NCCN clinical practice guidelines in oncology[J].Natl Compr Canc Netw,2022,20(5):497-530. [4] 马子骞,巫燕芬,魏武斌,等.非小细胞肺癌骨转移患者发生骨相关事件风险的预测模型[J].中医药导报,2022,28(7):106-110. [5] 洪方正,胡若愚,薛涛.肺癌骨转移机制的研究进展[J].东南大学学报(医学版),2021,40(5):714-720. [6] 郑庆中,苏洁敏,李小玲,等.~(18)F-FDG PET/CT显像对多发性骨髓瘤与骨转移瘤的鉴别诊断价值[J].中国实验血液学杂志,2020,28(4):1267-1271. [7] 卢纪杰,刘彦良.肺癌骨转移治疗新进展[J].临床医药文献电子杂志,2019,6(87):197-198. [8] Motegi K,Matsutomo N,Yamamoto T,et al.Evaluation of bone metastasis burden as an imaging biomarker by quantitative single-photon emission computed tomography/computed tomography for assessing prostate cancer with bone metastasis:a phantom and clinical study[J].Radiol Phys Technol,2020,13(3):219-229. [9] Wang S,Niu X,Bao X,et al.The PI3K inhibitor buparlisib suppresses osteoclast formation and tumour cell growth in bone metastasis of lung cancer,as evidenced by multimodality molecular imaging[J].Oncol Rep,2019,41(5):2636-2646. [10] Chen Z,Chen X,Wang R.Application of SPECT and PET/CT with computer-aided diagnosis in bone metastasis of prostate cancer:a review[J].Cancer Imaging,2022,22(1):18. [11] Kitajima K,Tsuchitani T,Takahashi Y,et al.Usefulness of quantitative bone single-photon emission computed tomography/computed tomography for evaluating the treatment response of bone metastasis in a lung cancer patient[J].Case Rep Oncol,2021,14(1):391-396. [12] Yamane T,Fukushima K,Shirotake S,et al.Test-retest repeatability of quantitative bone SPECT/CT[J].Ann Nucl Med,2021,35(3),338-346. [13] Ebrahim T,Hadebe B,Aldous C,et al.Segmented linear correlations between bone scan index and prostate cancer biomarkers,alkaline phosphatase,and prostate specific antigen in patients with a Gleason score ≥7[J].Medicine (Baltimore),2022,101(25):29515.